July 1, 1992Archives of Internal Medicine
A Critical Appraisal of Ticlopidine, a New Antiplatelet Agent
Key result
Ticlopidine was more effective than placebo for preventing stroke recurrences and more effective than aspirin for transient ischemic attacks and partial strokes.
Why the study?
Does ticlopidine reduce major morbidity and mortality in patients with atherosclerotic disorders compared to aspirin or placebo?
Population
Patients with atherosclerotic disorders from 4 randomized trials
Comparison
Ticlopidine vs Aspirin or placebo
Design
Systematic_review
Authors
Discussion
Loading...
Member takes
Implication
Ticlopidine offers an aspirin alternative for intolerant patients with stroke risk or unstable angina; reinforces trial-based guidance while leaving direct comparisons open.
Study Design
Type
Systematic Review
Structured PICO
Does ticlopidine reduce major morbidity and mortality in patients with atherosclerotic disorders compared to aspirin or placebo?
P
Population
A systematic review of four randomized trials evaluating ticlopidine versus aspirin or placebo for the prophylaxis of atherosclerotic disorders.
I
Intervention
Ticlopidine
C
Comparator
Aspirin or placebo
O
Outcome
Major morbidity and mortality (including recurrences after completed stroke, vascular death, nonfatal myocardial infarction)hard clinical
Ticlopidine is an effective alternative to aspirin for stroke prophylaxis and unstable angina in patients unable to tolerate aspirin, though it carries a higher risk of side effects including leukopenia.
Cite This Study
R. Brian Haynes (1992) conducted a systematic review in Atherosclerotic disorders. Ticlopidine vs. Aspirin or placebo was evaluated on Major morbidity and mortality. Ticlopidine was more effective than placebo for preventing stroke recurrences and more effective than aspirin for transient ischemic attacks and partial strokes.